This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 20 open trials.
In 107 locations
What is a Clinical Trial?
There are currently 20 open trials
- Belantamab mafodotin (GSK2857916) combinations for treatment of relapsed/refractory myeloma (DREAMM-6)
- A study evaluating the standard care of relapsed/refractory myeloma patients
- A study evaluating CCS1477 for the treatment of relapsed/refractory myeloma patients
- Oxford pre-cancerous disorders study (OxPLoreD)
- A study evaluating S65487 for the treatment of relapsed/refractory myeloma patients
- bb2121 CART-Cells in relapsed/refractory and high-risk myeloma (KarMMa-2)
- Using diffusion weighted MRI to measure myeloma disease burden and bone loss (LOOMIS)
- Exercise in transplant eligible myeloma patients (PERCEPT)
- Venetoclax and dexamethasone in patients with relapsed or refractory myeloma (CANOVA)
- Trial of immunomodulatory therapy in high risk solitary bone plasmacytoma (IDRIS)
- Selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma patients (MUK twelve)
- Tanezumab for bone pain in myeloma
- Donor lymphocyte infusion after stem cell transplant in myeloma (ProT4).
- CC-92480 in combination with dexamethasone in relapsed and refractory multiple myeloma
- AZD4573 in relapsed or refractory myeloma
- Ixazomib, pomalidomide and dexamethasone for relapsed and/or refractory myeloma patients
- Observational evaluation of myeloma patients (PREAMBLE)
- Melflufen and dexamethasone in myleoma patients refractory to lenalidomide (OCEAN trial)
- CC-220 (iberdomide) as a monotherapy and in combination with other treatments
- Myeloma XII (ACCoRd)
Trial Title:
Belantamab mafodotin (GSK2857916) combinations for treatment of relapsed/refractory myeloma (DREAMM-6)
Treatments:
GSK2857916
Lenalidomide (Revlimid)
Dexamethasone
Myeloma stage:
Relapsed, Refractory
Trial phase:
II
Summary:
This trial is investigating the safety and effectiveness of belantamab mafodotin (GSK2857916) when used in combination with lenalidomide (Revlimid®) and dexamethasone or bortezomib (Velcade®) and dexamethasone for the treatment of relapsed/refractory myeloma.
The trial will consist of two parts. The first part of the trial will test increasing doses to identify the best dose level and schedule. The second part of the trial will test the best doses identified in part one in a larger group of patients.
Locations:
Royal Cornwall Hospital, Truro;
University College Hospital, London
Who can enter the study?:
Relapsed/refractory myeloma patients who have had at least one prior treatment.
What's involved?:
Patients will be randomised to receive either belantamab mafodotin with lenalidomide and dexamethasone (Group A) or belantamab mafodotin with bortezomib and dexamethasone (Group B).
Patients in Group A will receive the combination treatment until there are signs of disease progression or treatment is discontinued for other reasons.
Patients in Group B will receive the combination treatment for up to eight cycles followed by belantamab mafodotin monotherapy until there are signs of disease progression or treatment is discontinued for other reasons.
Patients will be required to attend outpatient clinics for regular check-ups and blood tests.
Patients will be followed up for up to 4.5 years.
Clinical Information
(for Medical Professionals):
This two-part dose escalation and expansion trial in relapsed/refractory myeloma will evaluate the safety and tolerability profile of belantamab mafodotin when administered in combination with either lenalidomide and dexamethasone or bortezomib and dexamethasone.
For more information, click here.
Find out more about Myeloma UK:
Visit www.myeloma.org.uk